General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises the Underwriters in Fusion Pharmaceuticals’ Initial Public Offering

June 30, 2020
A capital markets team advised the underwriters in the clinical-stage oncology company's offering.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, has announced the pricing of its initial public offering of 12,500,000 common shares at a public offering price of $17.00 per share. All of the shares are being offered by Fusion. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Fusion, are expected to be $212.5 million. In addition, Fusion has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the initial public offering price.

Latham & Watkins LLP represents the underwriters in the initial public offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Adam Johnson, Angel Marcial and Tyler Mills.